Sitagliptin

J. Matthes; M. Faust

doi:10.1055/s-0028-1091266

DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis

Dtsch Med Wochenschr 2008; 133(43): 2233-2237
DOI: 10.1055/s-0028-1091266

Arzneimittel & Pharmakotherapie | Review article

Diabetologie
© Georg Thieme Verlag KG Stuttgart · New York

Sitagliptin

DPP-4-Inhibitoren als sinnvolle Erweiterung der oralen Diabetestherapie?Sitagliptin DPP-4 Inhibitors as expedient extension of oral diabetes treatment?J. Matthes¹ , M. Faust²

¹Institut für Pharmakologie, Universität zu Köln
²Klinik II und Poliklinik für Innere Medizin, Uniklinik Köln

Abstract

Schlüsselwörter

antidiabetische Therapie - Diabetes mellitus - GLP-1 - Inkretin

Keywords

antidiabetic therapy - diabetes mellitus - GLP-1 - incretin

Volltext

Referenzen

Literatur

1 Ahmad S R, Swan J. Exenatide and rare adverse events. N Engl J Med. 2008; 358 1970-1971
2 Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res. 2004; 36 867-876
3 Amori R E, Lau J, Pittas A G. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. Systematic Review and Meta-analysis. JAMA. 2007; 298 194-206
4 Aronoff S L, Berkowitz K, Shreiner B, Want L. Glukose metabolism and regulation: beyond insulin and Glukagon. Diabetes Spectr. 2004; 17 183-190
5 Berthold H K, Gouni-Berthold I, Bestehorn K, Böhm M, Krone W. Kardiovaskuläre Risikofaktoren bei Typ-2-Diabetikern in Deutschland – ein Versorgungsparadox. Dtsch Arztebl. 2007; 104 A861-A867
6 Buse J B, Henry R R, Han J. et al . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27 2628-2635
7 Deacon C F, Holst J J. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol. 2006; 38 831-844
8 Elahi D, McAloon-Dyke M, Fukagawa N K. et al . The insulinotropic actions of Glukose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7 – 37) in normal and diabetic subjects. Regul Pept. 1994; 51 63-74
9 He Y L, Wang Y, Bullock J M. et al . Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007; 47 633-641
10 Henness S, Keam S J. Vildagliptin. Drugs. 2006; 66 1989-2001
11 Herman G A, Bergman A, Stevens C. et al . Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma Glukose levels following an oral Glukose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006; 91 4612-4619
12 Kolligs F, Fehmann H C, Goke R, Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9 – 39) amide. Diabetes. 1995; 44 16-19
13 Lewis J T, Dayanandan B, Habener J F, Kieffer T J. Glukose-dependent insulinotropic polypeptide confers early phase insulin release to oral Glukose in rats: demonstration by a receptor antagonist. Endocrinology. 2000; 141 3710-3716
14 Lyseng-Williamson K A. Sitagliptin. Drugs. 2007; 67 587-597
15 Mojsov S, Weir G C, Habener J F. Insulinotropin: glucagon-like peptide I (7 – 37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987; 79 616-619
16 Nathan D M. Finding new treatments for Diabetes – How many, how fast … how good?. N Engl J Med. 2007; 356 437-440
17 Nauck M A, Heimesaat M M, Orskov C, Holst J J, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7 – 36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91 301-307
18 Nauck M A, Homberger E, Siegel E G. et al . Incretin effects of increasing Glukose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986; 63 492-498
19 Nauck M A, Meininger G, Sheng D, Terranella L, Stein P P. Sitagliptin Study 024 Group . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007; 9 194-205
20 Nielsen L L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today. 2005; 10 703-710
21 Orskov C, Holst J J, Knuhtsen S, Baldissera F G, Poulsen S S, Nielsen O V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986; 119 1467-1475
22 Pratley R E, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007; 23 919-931
23 Reuter H, Erdmann E. Exenatid – ein Inkretin-Mimetikum zur Behandlung des Diabetes mellitus Typ 2. Dtsch Med Wochenschr. 2007; 132 571-574
24 Scrocchi L A, Brown T J, MacLusky N. et al . Glukose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996; 2 1254-1258
25 Toft-Nielsen M B, Damholt M B, Madsbad S. et al . Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001; 86 3717-3723
26 Prospective Diabetes Study (UKPDS) Group . UK -- Intensive blood-Glukose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352 837-853

Dr. Jan Matthes

Institut für Pharmakologie, Universität zu Köln

Gleueler Straße 24

50931 Köln

Telefon: 0221/4785-674

Fax: 0221/4785-022

eMail: jan.matthes@uni-koeln.de